{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:21:30Z","timestamp":1782476490350,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"DOI":"10.7759\/cureus.107914","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:04:06Z","timestamp":1777424646000},"source":"Crossref","is-referenced-by-count":1,"title":["Leptomeningeal Carcinomatosis During Dose-Reduced Osimertinib Therapy in Epidermal Growth Factor Receptor (EGFR) L858R-Mutated Lung Adenocarcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Yu","family":"Tsukasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.05.023","article-title":"Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis","volume":"89","author":"Kuiper JL","year":"2015","unstructured":"Kuiper JL, Hendriks LE, van der Wekken AJ, et al.. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer. 2015, 89:255-61. 10.1016\/j.lungcan.2015.05.023","journal-title":"Lung Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29668","article-title":"Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: a systematic review and meta-analysiss","volume":"10","author":"Bian DJ","year":"2024","unstructured":"Bian DJ, Lazaratos AM, Maritan SM, et al.. Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: a systematic review and meta-analysiss. Heliyon. 2024, 10:e29668. 10.1016\/j.heliyon.2024.e29668","journal-title":"Heliyon"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2482\/haigan.36.879","article-title":"Leptomeningeal carcinomatosis in patients with lung cancer (Article in Japanese)","volume":"36","author":"Kimura K","year":"1996","unstructured":"Kimura K, Sakai H, Sumimoto H, et al.. Leptomeningeal carcinomatosis in patients with lung cancer (Article in Japanese). Japanese J Lung Cancer. 1996, 36:879-883. 10.2482\/haigan.36.879","journal-title":"Japanese J Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li YS","year":"2016","unstructured":"Li YS, Jiang BY, Yang JJ, et al.. Leptomeningeal metastases in patients with NSCLC with EGFR mutations. J Thorac Oncol. 2016, 11:1962-9. 10.1016\/j.jtho.2016.06.029","journal-title":"J Thorac Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.1999.0119","article-title":"Leptomeningeal carcinomatosis","volume":"25","author":"Grossman SA","year":"1999","unstructured":"Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999, 25:103-19. 10.1053\/ctrv.1999.0119","journal-title":"Cancer Treat Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7","article-title":"Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients","volume":"49","author":"Wasserstrom WR","year":"1982","unstructured":"Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982, 49:759-72. 10.1002\/1097-0142(19820215)49:4&lt;759::aid-cncr2820490427&gt;3.0.co;2-7","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park S","year":"2024","unstructured":"Park S, Baldry R, Jung HA, et al.. Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM). J Clin Oncol. 2024, 42:2747-56. 10.1200\/JCO.24.00708","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou VA","year":"2020","unstructured":"Papadimitrakopoulou VA, Mok TS, Han JY, et al.. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020, 31:1536-44. 10.1016\/j.annonc.2020.08.2100","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2482\/haigan.54.806","article-title":"A case of lung adenocarcinoma with gefitinib-resistant carcinomatous meningitis exhibiting the dose-dependent effects of erlotinib (Article in Japanese)","volume":"54","author":"Yajima T","year":"2014","unstructured":"Yajima T, Jingu D, Ubukata S, et al.. A case of lung adenocarcinoma with gefitinib-resistant carcinomatous meningitis exhibiting the dose-dependent effects of erlotinib (Article in Japanese). Japanese J Lung Cancer. 2014, 54:806-11. 10.2482\/haigan.54.806","journal-title":"Japanese J Lung Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv270","article-title":"First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study","volume":"26","author":"Wu YL","year":"2015","unstructured":"Wu YL, Zhou C, Liam CK, et al.. First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015, 26:1883-9. 10.1093\/annonc\/mdv270","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001443","article-title":"Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report","volume":"34","author":"Tan X","year":"2023","unstructured":"Tan X, Chen S, He L, Huang M, Zhang X. Successful osimertinib rechallenge after severe thrombocytopenia caused by osimertinib combined with sitagliptin: a case report. Anticancer Drugs. 2023, 34:791-6. 10.1097\/CAD.0000000000001443","journal-title":"Anticancer Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001424","article-title":"Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report","volume":"34","author":"Hu Y","year":"2023","unstructured":"Hu Y, Quan YP, Duan YW, et al.. Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced severe thrombocytopenia: a case report. Anticancer Drugs. 2023, 34:455-9. 10.1097\/CAD.0000000000001424","journal-title":"Anticancer Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2482\/haigan.59.46","article-title":"Successful dose-reduction therapy for osimertinib-induced neutropenia in EGFR-mutant lung adenocarcinoma: a report of two cases","volume":"59","author":"Nakamura Y","year":"2019","unstructured":"Nakamura Y, Hataji O, Suzuki Y, et al.. Successful dose-reduction therapy for osimertinib-induced neutropenia in EGFR-mutant lung adenocarcinoma: a report of two cases. Japanese J Lung Cancer. 2019, 59:46-52. 10.2482\/haigan.59.46","journal-title":"Japanese J Lung Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough N","year":"2021","unstructured":"Colclough N, Chen K, Johnstr\u00f6m P, et al.. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021, 27:189-201. 10.1158\/1078-0432.CCR-19-1871","journal-title":"Clin Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/477514-leptomeningeal-carcinomatosis-during-dose-reduced-osimertinib-therapy-in-epidermal-growth-factor-receptor-egfr-l858r-mutated-lung-adenocarcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:04:06Z","timestamp":1777424646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/477514-leptomeningeal-carcinomatosis-during-dose-reduced-osimertinib-therapy-in-epidermal-growth-factor-receptor-egfr-l858r-mutated-lung-adenocarcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.107914","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}